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 Materials and Methods 
 
Plasmid and strain construction 
Standard molecular biology cloning techniques were used to construct all plasmids (53). 
DNA synthesis was performed by Integrated DNA Technologies (Coralville, IA). All enzymes, 
including restriction enzymes and ligases, were obtained through New England Biolabs 
(Ipswich, MA). PCRs were performed with Expand High Fidelity PCR system (Roche, 
Indianapolis, IN) according to the manufacturer’s instructions. Ligation products were 
electroporated with a GenePulser XCell (Bio-Rad, Hercules, CA) into an E. coli DH10B strain 
(Invitrogen, Carlsbad, CA), where cells harboring cloned plasmids were maintained in Luria-
Bertani media containing 50 mg/ml ampicillin (EMD Chemicals). All cloned constructs were 
sequence verified by Laragen, Inc. (Santa Monica, CA). All confirmed plasmids were 
transformed into the appropriate yeast strains via standard lithium acetate procedure (54). 
All reporter plasmids expressing GFP were constructed from pCS321 (URA selection; 
fig. S12A and table S4) (24). Yeast promoters pADH1, pCYC1, pTEF1m7 (pC) (55), and pFUS1 
(pFB) (56) were PCR amplified from plasmid templates as specified and cloned into unique SacI 
(or NotI) and BamHI restrictions sites in pCS321 using promoter-specific primers (table S5).  
Plasmids for galactose-titration of pathway regulators were constructed from pCS1128 
(TRP selection), which harbors pGAL1-yEGFP-CYCt with an ON state RNA transducer control 
in the 3’ UTR between AvrII and XhoI (fig. S12B and table S6). Yeast mating pathway genes 
(STE4, STE50, STE11, STE7, FUS3, MSG5) were cloned into this construct between AvrII and 
BamHI, replacing yEGFP, using gene-specific primers to amplify the desired fragments from 
plasmid and genomic templates (table S5) (20, 57). Undesired restriction sites in the mating 
genes (e.g., XhoI in FUS3 and STE4, AvrII in STE7) were removed by site-directed mutagenesis 
using QuikChange II Site-directed mutagenesis kit (Agilent, Santa Clara, CA), according to the 
manufacturer’s instruction with appropriate primers (table S7).  
The single-cassette negative and positive diverters (positive: pC/FB-Ste4-SXtc; negative: 
pC/FB-Msg5-SXth) were constructed by cloning MSG5 and STE4 into the GFP-expressing 
constructs with the appropriate promoters to replace yEGFP via AvrII and BamHI restriction 
sites as described above for the galactose-titration constructs. The RNA transducers (i.e., 
ribozyme devices) and appropriate controls (table S8) were PCR amplified from plasmid 
templates using the appropriate primers (table S9) subsequently inserted into the 3’ UTR of these 
constructs via the unique restriction sites AvrII and XhoI, located immediately downstream of 
the gene stop codon as described previously (table S10 and S11) (24). The ON and OFF state 
controls for the RNA transducers correspond to the inactive and active ribozyme controls 
(representing the fully ‘on’ and ‘off’ gene expression states from the devices) as previously 
described (24). RNA transducers were previously constructed and characterized as described (24, 
35) except for S3tc. S3tc was cloned into pCS1748 downstream of the reporter cassette (pTEF1-
GFP) between AvrII and XhoI (35). To build pCS2450, S4tc was cloned into pCS1748 via AvrII 
and XhoI utilizing the primer Switch.NheI.FWD to insert a NheI site into the PCR insert. 
S1OFFth (with AvrII and XhoI 3’ and 5’ ends, respectively) was subsequently cloned into 
pCS2450 via NheI (compatible with AvrII sticky ends) and XhoI, ultimately removing the NheI 
site in the final construct pCS2451. S3tc was transformed into CSY3 and characterized as 
previously described (35). 
The dual-cassette negative and positive diverters (positive feedback: pFB-Ste4-SXtc; 
resistance: pC-Msg5-SXth) were constructed by cloning the appropriate expression modules into 
the dual-cassette plasmid pCS2094 (35) (URA selection; fig. S13A and table S12). The positive 
feedback module (pFB-Ste4-S2tc) was amplified via PCR from the single-cassette positive 
diverter plasmid with primers pFUS1.ClaI.pCS2094.FWD (5’-CCAATCTCAGAGGCTGAGTC 
TC) and Switch3’.XhoI.pCS2094.REV (5’-AAAACTCGAGTTTTTATTTTTCTTTTTGCTGTT 
TCG) and cloned into the unique ClaI and XhoI restriction sites in pCS2094 to construct 
pCS2515 (fig. S13B). Tetracyline-responsive RNA transducers and appropriate controls (table 
S8) were inserted into the 3’ UTR of STE4 via the unique restriction sites AvrII and XhoI, 
located immediately downstream of the STE4 stop codon as described previously (24). 
Resistance expression modules (pC-Msg5-SXth) were PCR amplified from the single-cassette 
negative diverter plasmids (table S10) with primers pTEF7.FWD (5’-AAGAGCTCATAGCTTC 
AAAATGTCTCTACTCCTTTTT) and CYC1t.NotI.REV (5’-AAAAGCGGCCGCTATATTAC 
CCTGTTATCC) and cloned into the unique SacI and NotI restriction sites in constructs 
harboring the positive feedback modules (fig. S13C and table S12).  
A second dual-cassette plasmid (TRP selection) was constructed for the negative 
feedback and booster modules (negative feedback: pFB-Msg5-SXth; booster: pC-Ste4-SXtc). A 
dual-expression plasmid, pCS2521, harboring the positive feedback module with OFF state 
control and a second expression cassette bearing pTEF1-mCherry-CYC1t was digested with SacI 
and KpnI. The dual-expression cassette fragment was gel extracted and inserted via these same 
unique restriction sites into pCS1128 (TRP selection) to construct pCS2540. Negative feedback 
modules (pFB-Msg5-SXth) were PCR amplified from the single-cassette negative feedback 
diverter plasmids (table S10) using primers Msg5.K2.FWD (5'-AAAGGATCCAATTAATAGT 
GCACATGCAATTTCAC) and Switch3’.XhoI.pCS2094.REV and cloned into the unique 
BamHI and XhoI restriction sites in pCS2540 (fig. S14A). Booster expression modules (pC-Ste4-
SXtc) were PCR amplified from the single-cassette booster diverter plasmids (table S11) with 
primers pTEF7.FWD and CYC1t.NotI.REV and cloned into the unique SacI and NotI restriction 
sites in constructs harboring the negative feedback modules (fig. S14B and table S13). 
Additionally, single-cassette booster diverters (pC-Ste4-SXtc) were cloned into the pCS1128 
backbone (TRP selection) via SacI and KpnI (table S14) for pairing with pCS2094-based 
backbones (URA selection). 
The galactose-titration studies were performed in yeast strains that have the galactose 
transporter GAL2 knocked out. The pFUS1-yEGFP3-CYC1t cassette from pCS1124 was cloned 
into pCS1391, a loxP integrating vector (58), via the unique SacI and KpnI restriction sites to 
construct pCS2292 (table S15). The pFUS1-yEGFP3-CYC1t expression cassette from pCS2292 
was subsequently chromosomally integrated into yeast strain CSY364 (EY1119; W303a ∆sst1 
∆kss1::HIS3) (59) via homologous recombination to construct yeast strain CSY532 (W303a 
∆sst1 ∆kss1::HIS3 gal2::FUS1p-yEGFP3-loxP-KanR-loxP) (table S16). Briefly, the pFUS1-
yEGFP3-loxP-KanR-loxP cassette was PCR amplified from pCS2292 using forward and reverse 
primers harboring 60 nts of homology to the GAL2 locus (table S17). Yeast strain CSY364 was 
transformed with 12 g of gel purified PCR product and plated on G418 plates to select for the 
GAL2 knock-out, integrated pFUS1-GFP reporter strain CSY532. The characterization strain for 
the molecular network diverters (CSY840, W303a ∆sst1 ∆kss1::HIS3 trp1::FUS1p-yEGFP3-
loxP-KanR-loxP) was constructed as described for CSY532, except primers specific to the TRP1 
locus were used for integrating the reporter cassette (table S17).   
 
Measuring promoter and RNA transducer activities 
 To characterize promoter activities, promoter-GFP fusions were constructed as described 
(table S4) and transformed into CSY364. Cells were inoculated into the appropriate dropout 
media, grown overnight at 30°C, and back diluted into fresh media. For pFB, GFP values were 
determined in the absence (pFB-) and presence (pFB+) of saturating α factor 3 h following 
stimulation. Following 6 h of growth post-back dilution, GFP fluorescence levels from the pX-
yEGFP3 reporter were evaluated via flow cytometry using a Cell Lab Quanta SC flow cytometer 
(Beckman Coulter, Fullerton, CA). GFP was exited from a 488 nm laser and emission was 
measured from 520/40 nm bandpass filter with a PMT setting of 5.0. Cells were gated for 
viability based on side scatter and EV. For each sample, the GFP values of 10,000 viable cells 
were measured. Cells were then gated for GFP levels above background. Flow cytometry data 
was analyzed using the FlowJo v.10 (Tree Star, Inc.) software package. Normalized GFP 
expression is reported as the geometric mean GFP value from cells harboring the specified 
construct normalized to that of the control (cells harboring the pC construct). RNA transducers 
were characterized as previously described (35). Briefly, transducers regulating the pTEF1-
yEGFP3 reporter were characterized for GFP fluorescence on a Quanta flow cytometer as 
described above. Transducer activity was determined as the geometric mean of the GFP 
fluorescence based for population gate above background using FlowJo v.10 (Tree Star, Inc.) 
software package, and normalized to the geometric mean of the GFP fluorescence of the ON 
positive control (sTRSV Ctrl). 
 
 
 
Calculating relative regulator expression 
For non-feedback constructs, relative regulator (Ste4/Msg5) expression was calculated 
from measured values of the relative promoter activities (Fig. 2C) and the various RNA 
transducer activities (Fig. 2, D and E). Briefly, for each promoter-transducer pairing the 
calculated expression amount was determined as the relative GFP expression (from the 
promoter) multiplied by the relative GFP expression (from the transducer at the appropriate 
signal molecule concentration). Relative regulator expression values were determined as the 
calculated expression amount for the indicated construct normalized to that of a construct with 
the pairing of the pC promoter and ON RNA transducer control. For the positive feedback 
constructs (pFB-Ste4-SX), predicted expression of Ste4 was calculated using the measured 
transducer activity and the pFB promoter activity in the absence of pheromone to simulate the 
initial (t=0) Ste4 expression from the system. For the negative feedback constructs (pFB-Msg5-
SX), the value of the relative promoter activity was determined from relative GFP expression 
levels (or normalized pathway activity values) in reporter strains (pFUS1-GFP) harboring Msg5 
constructs under feedback control (pFB) paired with the various transducers (SX).  
 
Evaluating selection of mating resistance population 
The selection of a mating resistant population over time from cell populations undergoing 
high levels of growth arrest was evaluated in cells expressing Ste4 from the galactose-inducible 
promoter (pGAL-STE4-ON) and blank plasmid control in yeast strain CSY532. Cells were 
inoculated into the appropriate dropout media, grown overnight at 30°C, and back diluted into 
fresh media to an OD600 of <0.1. Briefly, cells were grown for 48 h in the presence of pheromone 
(100 nM). Cells were back diluted into fresh media at 0, 6, 18, 30 and 42 h maintaining the 
pheromone concentration. Mean fluorescence values for GFP were measured by flow cytometry 
as described previously at 0, 6, 24, 30, and 48 h. For measurement time points corresponding to 
back-dilution time points, cells were measured prior to back dilution. Values represent the mean 
of at least three biological replicates and error bars represent standard deviation. Halo assays 
were performed as described previously at the indicated galactose concentrations after 48 h of 
growth. Representative images are presented from experiments performed in triplicate. 
Additionally, cells expressing Ste4 from the galactose-inducible promoter (pGAL-STE4-
ON) were grown in the presence or absence of galactose (0, 2%). Cells were back diluted into 
fresh media at 0, 12, 24, 36 and 48 h maintaining the galactose concentration. Mean fluorescence 
values for GFP were measured by flow cytometry as described previously at time points 0, 6, 12, 
30, 36, and 54 h. For measurement time points corresponding to back-dilution time points, cells 
were measured prior to back dilution. Values represent the mean of at least three biological 
replicates and error bars represent standard deviation. Halo assays were performed as described 
previously at the indicated galactose concentrations after 54 h of growth. Representative images 
are presented from experiments performed in triplicate. 
 
Determining resolution and variation in positive diverter networks.  
Resolution was determined by setting a gate at the lowest ~5% of the triggered 
population. The percentage of cells in the population falling above this gate were determined for 
both triggered and untriggered cells (untriggered/triggered: 0/1 mM tetracycline). Resolution is 
reported as the ratio of the % of triggered cells that fell above this gate to the % of total cells (% 
triggered and % untriggered cells) that fell above this gate. The coefficient of variation (CV) was 
determined for viable cells above background fluorescence using the CV function in FlowJo v.10 
(Tree Star, Inc.) software package. Values were normalized to the CV cells harboring the blank 
plasmid control stimulated with saturating pheromone (100 nM). Values represent mean of at 
least three biological replicates and error bars represent standard deviation. 
 
Measuring mating efficiencies 
Quantitative mating assays were performed as previously described (60). Briefly, 
experimental yeast strains (MATa) harboring the indicated constructs to be tested for mating 
efficiency were grown to an OD600 of 0.4-0.8 and back diluted into the appropriate media 
containing the indicated concentration of signal molecule (theophylline or tetracycline). 
Following 3 h of growth post-back dilution, 1x 10
6
 cells of the experimental strain were mixed 
with 1x10
7
 cells of the MAYA12 (MATα –lys1) tester strain (60). The mixture of cells was 
collected on a 0.45 µm pore, 25 mm nitrocellulose filter disc and placed on YPD plates for 5 h at 
30
o
C. Cells were resuspended by vortexing the disc in 1 mL of yeast nitrogen base (YNB). The 
resuspended cell mixture was serially diluted 1:10 in YNB to make dilutions 10
-1
, 10
-2
, 10
-3
, and 
10
-4
. To titer diploids, 200 µl of the 10
-2
 dilution was plated on total dropout plates. To titer the 
experimental strain, 200 µl of the 10
-3
 and 10
-4
 dilutions were plated on –LYS plates. Mating 
efficiency was calculated as the number of diploids normalized by the number of colonies from 
the –LYS plates (experimental strain and diploids). Data represents mean values from three or 
more independent replicates. Error bars represent the standard deviation of at least three 
replicates. P-values were determined using a two-tailed t-test of the compared data sets. 
 
 
 
Supporting Text 
Text S1: The selection of a mating-resistant population over time from cells programmed 
for high levels of growth arrest 
Pathway activity was examined as a function of the calculated Ste4 expression to identify 
the threshold level at which cell fate diverges. The data shows a steady increase in pathway 
activity with increasing relative Ste4 expression up to a threshold value followed by a sharp drop 
(fig. S3A). The drop in pathway activity coincides with the divergence of fate observed in the 
halo assays. Only cells conditionally induced to higher Ste4 expression over the course of the 
assay exhibit high pathway activity, while cells programmed for invariantly high Ste4 expression 
exhibit low pathway activity, suggesting that over longer time periods high Ste4 expression may 
select for cells with inactive pathways. For example, despite being programmed for constitutive 
arrest the ON state control for Ste4 expression under the feedback architecture (pFB-Ste4-ON) 
exhibited low pathway activity and significant growth across the entire plate in halo assays 
indicating insensitivity to pheromone (Fig. 3A). These data suggest that over longer time periods 
high Ste4 expression may select for mating-resistant cells. Alternately, cells may escape 
persistent cell cycle arrest induced via high Ste4 expression via mutations inhibiting the 
expression of Ste4 or even via plasmid loss. For example, the ON state control for constitutive 
Ste4 expression (fig. S4 and S5A) demonstrates extra-halo growth at a reduced cell density 
indicating that a small fraction of the plated cells grow and respond to pheromone. Cells may 
utilize a combination of strategies to counteract constitutive cell-cycle arrest leading to diverse 
phenotypes that vary both across and within constructs and cultures representing a mix of 
selective pressures and hysteresis (fig. S5B). 
While plasmid loss and/or mutation may account for the development of a population of 
cells displaying the wild-type phenotype in cells programmed for high Ste4 expression, these 
factors are insufficient to account for the uniform growth across the plate observed in halo assays 
(Fig. 3A). We postulated that strong Ste4 overexpression places selective pressure against cells 
with highly active pathways via growth arrest, such that over time the population is dominated 
by cells resistant to pathway activation and subsequent growth arrest. Consequently, cells 
harboring programs with constitutively high Ste4 expression display a low fluorescence profile 
from the pFUS1-GFP reporter and exhibit growth within the expected halo region indicating 
resistance to pheromone-induced cell cycle arrest. To test this hypothesis, we monitored the 
growth arrest behavior and GFP profile of cells harboring Ste4 galactose titration plasmid 
(pGAL1-Ste4-ON) or a blank plasmid (pCS1071). Cells were stimulated either via saturating 
pheromone for 48 h (fig. S3, B and C) or grown in the presence of galactose for 54 h (fig. S3, D 
and E). Following an initial increase in pathway activity, the activity of stimulated cells dropped 
to unstimulated levels (fig. S3, B and D). Cells persistently activated with pheromone or high 
Ste4 expression failed to form the characteristic halo indicating pheromone fails to induce cell 
cycle arrest in these cells (fig. S3, C and E). Cells naïve to galactose and pheromone stimulation 
(i.e., without previous exposure to either pheromone or galactose) maintained their 
responsiveness to both pheromone and galactose. Taken together the data confirm that persistent 
stimulation results in a cell population resistant to mating pathway activation. These results 
highlight the utility of genetic programs that run quiescently until activated for applications in 
which the program necessarily modulates cellular processes that place selection pressure on the 
population, such as growth rate and/or viability.  
 
 
Supplementary Figures 
 
Figure S1. Raw flow cytometry histograms for pathway component sensitivity analysis and 
single molecular network diverters  
(A, B) Flow cytometry histograms for cells harboring the indicated pathway genes overexpressed 
from pGAL1 in the presence (+gal) or absence (-gal) of 1% galactose. Pathway activation is 
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measured in the absence of 100 nM pheromone (A, -α) and pathway attenuation is measured in 
the presence of 100 nM pheromone (B, +α). (C) Flow cytometry histograms for cells harboring 
the indicated positive feedback diverters with various transducers in the absence (-tc) or presence 
(+tc) of 1 mM tetracycline and in the absence of pheromone (-α). (D) Flow cytometry histograms 
for cells harboring the indicated resistance diverters with various transducers in the absence (-th) 
or presence (+th) of 5 mM theophylline and in the presence of 100 nM pheromone (+α). The data 
suggest that while the population-level pathway activity response to changes in Msg5 is graded, 
individual cells respond in a more “all-or-none” manner.  Further, the variation in pathway 
activity may be magnified by the presence of external antagonism (i.e., saturating pheromone), 
cell-to-cell variation in Msg5 expression, and the potency of Msg5 as a regulator.  
 Figure S2. Titratable regulators of pathway activity in the yeast mating pathway route to 
alternate fates 
(A) In the absence of pheromone, Ste4 overexpression increases pathway activity in a galactose-
dependent manner, indicating it is a positive regulator. Overexpression of Ste4 routes cells to the 
mating fate characterized by pheromone-independent cell cycle arrest in halo assays. (B) Msg5 
overexpression reduces pathway activity in pheromone stimulated cells, indicating it is a 
negative regulator. Overexpression of Msg5 routes cells to the non-mating fate characterized by 
reduced halo formation. Pathway activity is measured via a pFUS1-GFP reporter. Cells were 
cultured in 0, 0.25, 0.5, 1, 2, or 3% galactose for 6 h after back dilution prior to measurement on 
a flow cytometer. To characterize Msg5 (B), cells were stimulated with saturating pheromone 3 h 
post-back dilution. To identify activating regulators, normalized pathway activity is reported as 
the geometric mean GFP value from cells harboring the specified construct in the absence of 
pheromone at the indicated galactose concentration normalized to that of the control (cells 
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harboring a blank plasmid in the presence of saturating pheromone at the corresponding 
galactose concentration). To identify attenuating regulators, normalized pathway activity from 
attenuating constructs is reported as described above, except cells are assayed in the presence of 
saturating pheromone. 
 Figure S3. Persistent pathway activation results in the selection of mating-resistant cells 
(A) Pathway activity increased with increasing Ste4 expression up to a threshold point. Above 
this threshold, pathway activity drops, indicating that strong Ste4 overexpression placed selective 
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pressure against cells through growth arrest such that cells resistant to pathway activation 
dominated the population over time. (B) Over time persistent stimulation with saturating 
pheromone results in a cell population dominated by cells unresponsive to pheromone. Cells 
harboring the construct pGAL1-Ste4-ON or a blank plasmid control were grown over 48 h in the 
presence of saturating pheromone. To maintain pheromone concentration and logarithmic 
growing conditions, cells were back diluted into fresh media every 12 h. Normalized pathway 
activity is reported as the geometric mean GFP value from cells harboring the specified construct 
at the indicated galactose concentration normalized to that of the control (cells harboring a blank 
plasmid in the presence of saturating pheromone in 0% galactose). (C) Halo assays indicate that 
over time persistent pheromone stimulation leads to a population dominated by cells resistant to 
pheromone-induced cell cycle arrest. Following 48 h growth in the presence of pheromone, halo 
assays were performed as described previously. (D) Over time high expression of Ste4 via the 
galactose-inducible system selects for cells resistant to Ste4-mediated pathway activation. Cells 
harboring the construct pGAL1-Ste4-ON were grown over 48 h in the presence or absence of 
galactose (0, 2%). To maintain galactose concentration and logarithmic growing conditions, cells 
were back diluted into fresh media every 12 h. (E) Halo assays indicate that over time persistent 
stimulation via Ste4 overexpression leads to a population dominated by cells resistant to 
pheromone-induced cell cycle arrest. Cells grown in the presence of galactose for 54 h show 
reduced responsiveness to galactose in halo assays with only slight decrease in density from 0% 
(-) to 2% (+) galactose. Cells grown for 54 h in the absence of galactose maintain responsiveness 
to both pheromone and galactose. Following 54 h growth in the presence of pheromone, halo 
assays were performed as described previously.  
  
     
Figure S4. Positive diverters without feedback exhibit weak routing to the mating fate 
A positive diverter without feedback, or booster diverter, (pC-Ste4-S4tc) exhibits wild-type fate 
in the absence of tetracycline and weak routing to the mating fate in response to tetracycline (-
/+tc: 0/1 mM tetracycline; -α: 0 nM α mating factor). Asterisk: The ON state control shows 
significant growth in the presence and absence of tetracycline indicating that cells harboring this 
diverter have escaped the programmed growth arrest expected due to high Ste4 expression (SOM 
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text S1). Normalized pathway activity from activating constructs is reported as the geometric 
mean GFP value from cells harboring the specified construct in the absence of pheromone at the 
indicated signal concentration normalized to that of the control (cells harboring a blank plasmid 
in the presence of saturating pheromone).  
     
Figure S5. Network diverters can be programmed to respond to different environmental 
signals through the RNA transducer component 
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(A) The positive diverter without feedback, or booster diverter, is modified to respond to a 
different environmental signal by replacing the tetracycline-responsive RNA transducer with a 
theophylline-responsive RNA transducer. The theophylline-responsive booster diverters exhibit 
increased pathway activity in response to theophylline. The booster diverter pC-Ste4-S4th 
exhibits wild-type fate in the absence of theophylline and weak routing to the mating fate in the 
presence of theophylline (-/+th: 0/5 mM theophylline; -α: 0 nM α mating factor). Normalized 
pathway activity from activating constructs is reported as the geometric mean GFP value from 
cells harboring the specified construct in the absence of pheromone at the indicated signal 
concentration normalized to that of the control (cells harboring a blank plasmid in the presence 
of saturating pheromone). (B) The positive feedback diverter is modified to respond to a 
different environmental signal by replacing the tetracycline-responsive RNA transducer with a 
theophylline-responsive RNA transducer. The theophylline-responsive positive feedback 
diverters exhibit slightly increased pathway activity in response to theophylline. The positive 
feedback diverter pFB-Ste4-S4th exhibits wild-type fate in the absence of theophylline and 
robust routing to the mating fate in the presence of theophylline. Asterisk: The ON state control 
shows significant growth in the presence and absence of theophylline indicating that cells 
harboring this diverter have escaped the programmed growth arrest due to high Ste4 expression 
(SOM text S1).  
 
 
 
   
Figure S6. Negative feedback diverters result in reduced pathway activity and a weak 
response to the trigger molecule 
No single negative feedback diverter (pFB-Msg5-SXth) exhibits robust routing between the wild-
type and non-mating fates (-/+th: 0/5 mM theophylline; +α: 100 nM α mating factor). 
Normalized pathway activity from attenuating constructs is reported as the geometric mean GFP 
value from cells harboring the specified construct in the presence of saturating pheromone at the 
indicated signal concentration normalized to that of the control (cells harboring a blank plasmid 
in the presence of saturating pheromone).  
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 Figure S7. Dual-router architectures based on integrating the positive feedback and 
resistance diverters fail to achieve dual fate routing 
(A) Combining positive feedback diverters (left: pFB-Ste4-OFF; center: pFB-Ste4-S2tc; right: 
pFB-Ste4-S4tc) with negative diverters without feedback, or resistance diverters, of varying 
strength (pC-Msg5-SXtc) inhibits pathway activation (-/+tc: 0/1 mM tetracycline; -α: 0 nM α 
mating factor). Normalized pathway activity from activating constructs is reported as the 
geometric mean GFP value from cells harboring the specified construct in the absence of 
pheromone at the indicated signal concentration normalized to that of the control (cells harboring 
a blank plasmid in the presence of saturating pheromone). (B) Pathway attenuation increases 
with increasing resistance strength (-/+th: 0/5 mM theophylline; +α: 100 nM α mating factor). 
Normalized pathway activity from attenuating constructs is reported as the geometric mean GFP 
value from cells harboring the specified construct in the presence of saturating pheromone at the 
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indicated signal concentration normalized to that of the control (cells harboring a blank plasmid 
in the presence of saturating pheromone). 
 
 
 
 
 
 
 
 
  
Figure S8. A dual-router architecture based on integrating the improved positive feedback 
diverter with reduced antagonism with resistance diverters fails to achieve dual fate 
routing 
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(A) Combining the positive feedback diverter designed for reduced antagonism (pFUS1-Ste4-
S3tc) with negative diverters without feedback, or resistance diverters, of varying strength (pC-
Msg5-SXth) inhibits pathway activation (-/+tc: 0/1 mM tetracycline). Inset shows that cells 
harboring the positive feedback diverter (pFUS1-Ste4-S3tc) paired with the resistance diverters 
(OFF, S2th) fail to route to the mating fate. In contrast, cells harboring the positive feedback 
diverter without a resistance cassette (none) route to the mating fate in response to 1 mM 
tetracycline. Normalized pathway activity from activating constructs is reported as the geometric 
mean GFP value from cells harboring the specified construct in the absence of pheromone at the 
indicated signal concentration normalized to that of the control (cells harboring a blank plasmid 
in the presence of saturating pheromone). (B) Pathway attenuation from resistance diverters of 
varying strength (pC-Msg5-SXth) paired with the positive feedback diverter that reduces positive 
feedback strength in response to theophylline (pFUS1-Ste4-S3tc) is similar to configurations 
with lower strength positive feedback modules (fig. S10; -/+th: 0/5 mM theophylline; +α: 100 
nM α mating factor). Normalized pathway activity from attenuating constructs is reported as the 
geometric mean GFP value from cells harboring the specified construct in the presence of 
saturating pheromone at the indicated signal concentration normalized to that of the control (cells 
harboring a blank plasmid in the presence of saturating pheromone).  
 Figure S9. A dual-router architecture based on integrating the amplifying diverter with the 
resistance diverter fails to route cells to the non-mating fate 
Cells harboring the amplifying diverter (positive feedback module: pFB-Ste4-S3tc; booster 
module: pC-Ste4-S4tc) and the negative diverter without feedback, or resistance diverter, (pC-
Msg5-S2th) fail to route cells to the non-mating fate (-/+: 0/20 mM theophylline). 
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 Figure S10. Constructing network architectures for robust performance  
(A) Incorporating resistance and negative feedback modules into positive diverter networks 
enhances resolution between triggered and untriggered cells. Resolution provides a metric for 
determining the enrichment of triggered cells relative to untriggered cells above a particular 
fluorescence level, thus providing a measure of certainty that a cell above a particular 
fluorescence level has been triggered. As resolution increases the fraction of untriggered cells 
overlapping with the triggered cell population decreases. Resolution was determined by setting a 
R
e
s
o
lu
ti
o
n
 
(%
 t
ri
g
g
e
re
d
 / 
(%
 t
ri
g
g
e
re
d
 +
 %
 u
n
tr
ig
g
e
re
d
c
e
ll
s
))
R
e
la
ti
v
e
 C
V
B
A
0.00
0.50
1.00
1.50
2.00
2.50
1 2 3 4
0.0
0.2
0.4
0.6
0.8
1.0
1 2 3 4
gate at the lowest ~5% of the triggered population. The percentage of cells in the population 
falling above this gate were determined for both triggered and untriggered cells 
(untriggered/triggered: 0/1 mM tetracycline). Resolution is reported as the ratio of the % of 
triggered cells that fell above this gate to the % of total cells (% triggered + % untriggered) that 
fell above this gate. No population overlap would result in full resolution (resolution = 1), and 
for entirely overlapping populations each population would contribute an equivalent percentage 
of cells resulting in a resolution of 0.5. (B) The introduction of resistance and negative feedback 
into positive diverters significantly reduces population heterogeneity. The coefficient of variation 
provides a metric for determining population heterogeneity. The coefficient of variation (CV) 
was determined for triggered cells (1 mM tetracycline) using the CV function in FlowJo v.10 
(Tree Star, Inc.) software package on the population gated viable and above background 
fluorescence. Values were normalized to the CV for the wild-type pathway stimulated with 
saturating pheromone (100 nM).  
 
 
 
 
 
 
 
 
 
 
  
Figure S11. Resistance strength and signal concentration tune activity of diverters to 
enable dual-fate routing 
(A) Pathway activation, (B) attenuation, and (C) cell fate routing as a function of increasing 
strength of the resistance module in the dual diverter (–/+tc: 0/1 mM tetracycline;  –/+th: 0/5 mM 
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theophylline; –/+α: 0/100 nM α mating factor). Routing to the non-mating and mating fates is 
enhanced with increasing levels of the environmental signals (blue: 1 mM tetracycline; dark 
blue: 2 mM tetracycline; red: 5 mM theophylline; dark red: 20 mM theophylline). Normalized 
pathway activity from activating constructs is reported as the geometric mean GFP value from 
cells harboring the specified construct in the absence of pheromone at the indicated signal 
concentration normalized to that of the control (cells harboring a blank plasmid in the presence 
of saturating pheromone). Normalized pathway activity from attenuating constructs is reported as 
the geometric mean GFP value from cells harboring the specified construct in the presence of 
saturating pheromone at the indicated signal concentration normalized to that of the control (cells 
harboring a blank plasmid in the presence of saturating pheromone).  
  
  
Figure S12. Plasmid maps of single-expression cassette plasmids  
Plasmid maps for (A) pCS321 and (B) pCS1128.  
B
A
 Figure S13. Plasmid maps of -URA dual-expression cassette plasmids 
Plasmid maps for (A) pCS2094, (B) pCS2515, and (C) pCS2515 with resistance module (pC-
Msg5-SXth).  
A
C
B
 Figure S14. Plasmid maps of –TRP dual-expression cassette plasmids 
Plasmid maps for (A) pCS2541 and (B) pCS2541 with booster module (pC-Ste4-SXtc).  
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Supplementary Tables 
Table S1. Fitted Hill function and parameters for Ste4 
 
 
*Basal term represents basal activity of the mating pathway. Vmax-Ste4 constrained to fit both pC 
and pFB. 
Table S2. Fitted Hill function and parameters for Msg5 
 
 
*Active term represents full activity of the mating pathway at 100 nM pheromone (saturated). 
 
 
 
 
Parameters pC-Ste4 pFB-Ste4
n 2.0 1.5
EC50-Ste4 0.21 0.02
Basal 0.07 0.07
Vmax-Ste4 0.45 0.45
Parameters pC-Msg5 pFB-Msg5
n 2.3 1.4
EC50-Msg5 0.025 0.024
Active 1.0 1.0
Vmax-Msg5 0.86 0.53
pFUS1 − GFP = 𝐵𝑎𝑠𝑎𝑙 + 𝑉        
[𝑆𝑡𝑒4] 
[𝐸𝐶       ] + [𝑆𝑡𝑒4] 
 
pFUS1 − GFP = 𝐴𝑐𝑡𝑖𝑣𝑒 − 𝑉        
[𝑀𝑠𝑔5] 
[𝐸𝐶       ] + [𝑀𝑠𝑔5] 
 
 Table S3. Model Species and Parameters    
 
 *LB = Lower bound, UB= Upper bound 
 
Species Description β (production)      LB UB
Fus1 Promoter activity, pathway output 0.001 1E-03 2
Fus3 MAPK, central hub in pathway 0.1 1E-03 1
Msg5 Native Msg5, negative regulator 0.01 1E-03 1
Ste4 Native Ste4, positive regulator 0.2 1E-04 0.5
Species Description δ (degadation) LB UB
Fus1 Promoter activity, pathway output 1 1E-03 3
Fus3 MAPK, central hub in pathway 0.7 1E-03 1
Msg5 Native Msg5, negative regulator 3 1E-03 5
Ste4 Native Ste4, positive regulator 2 1E-03 5
Rates Description Value LB UB
kα Rate constant for α-factor activation of Fus3 2 0.50 4
kFus3 Rate constant for  Fus3 activation of Fus1 1.3 1E-03 2
kSte4 Rate constant for Ste4 activation of Fus3 1 1E-03 5
kMsg5 Rate constant for Msg5 desphosphorylation of Fus3 10 1E-03 15
kc,Ste4 Rate constant for production of Ste4 from booster module 2 1E-03 5
kFB,Ste4 Rate constant for production of Ste4 from positive feedback module 2 1E-03 5
kc,Msg5 Rate constant for production of Msg5 from resistance module 2.5 1E-03 5
kFB,Msg5 Rate constant for production of Msg5 from negative feedback module 1.5 1E-03 5
Hill coefficients Description Value LB UB
n Hill coefficient for  α-factor effect on Fus3 2 1 5
nnf Hill coefficient for negative feedback loop,  Fus1 production of Msg5 1 1 5
npf Hill coefficient for positive feedback loop,  Fus1 production of Ste4 3 1 5
m Hill coefficient for Ste4 activation of Fus3 4 1 5
q Hill coefficient for Msg5 deactivation of Fus3 4 1 5
p Hill coefficient for Fus3 activation of Fus1 1 1 5
KM Description Value LB UB
KM,α Half-maximal concentration of α-factor (pheromone) 14 10 40
KM,Ste4 Half-maximal concentration of Ste4 0.5 1E-03 5
KM,Msg5 Half-maximal concentration of Msg5 0.05 1E-03 5
KM,Fus3 Half-maximal concentration of Fus3 1 1E-03 2
KM,Fus1,nf Half-maximal concentration of Fus1 for negative feedback loop 1 1E-03 5
KM,Fus1,pf Half-maximal concentration of Fus1 for positive feedback loop 0.1 1E-03 5
Synthetic Inputs Description Min Max
SFtc Tetracycline-transducer activity of positive feedback module 0 1
SCtc Tetracycline-transducer activity of booster module 0 1
SFth Theophylline-transducer activity of negative feedback module 0 1
SCth Theophylline-transducer activity of resistance module 0 1
  
Table S4. yEGFP plasmids 
 
 
Table S5. Promoter and gene-specific primers for cloning 
 
pCS #  Cassette 3'UTR Marker
pCS1128 pGAL1-yEGFP-ADH1t sTRSV Ctrl TRP
pCS321 pGAL1-yEGFP-ADH1t Empty URA
pCS1124 pFUS1 -yEGFP-ADH1t Empty URA
pCS1585 pTEF1 -yEGFP-ADH1t Empty URA
pCS2446 pTEF7 -yEGFP-ADH1t Empty URA
pCS2447 pCYC1-yEGFP-ADH1t Empty URA
pCS2448 pADH1-yEGFP-ADH1t Empty URA
pCS2449 pSTL1-yEGFP-ADH1t Empty URA
pCS1748 pTEF1-yEGFP-ADH1t Empty URA
pCS2450 pTEF1-yEGFP-L2b12tcNheI-ADH1t L2b12tc URA
pCS2451 pTEF1-yEGFP- L2b12tc-L2bOFF1-ADH1t L2b12tc-L2bOFF1 URA
Insert or 
PCR Product Primer Name Sequence
Template
pTEF7-FWD  5’- AA GAGCTC ATA GCT TCA AAA TGT CTC TAC TCC TTT TT
pTEF7-REV 5’- AAA GGATCC AAC TTA GAT TAG ATT GCT ATG CTT TCT TTC C
pDS71.FUS1-FWD 5'-TTT GCGGCCGC CCA ATC TCA GAG GCT GAG TCT
pDS71.pFUS1-REV 5'-TTT GGATCC TTT GAT TTT CAG AAA CTT GAT GGC
pADH1-FWD 5’- AA GAGCTC AGC TCG ATA TCC TTT TGT TGT TTC C
pADH1-REV 5’- AA GGATCC ATT GTA TGC TTG GTA TAG CTT GAA ATA TTG TG
pCYC1-FWD  5’- AA GAGCTC CTC GGT ACC CTA TGG CAT GCA TGT
pCYC1-REV 5’- AAA GGATCCACGAATTGATCCGGTAATTTAGTGTGTG
Ste4.k2.FWD 5’- AAA GGATCC A AT TAA TA ATG GCA GCA CAT CAG ATG GAC 
Ste4.REV 5'-AAA  CCTAGG CTATTGATAACCTGGAGACCATA
Ste50. k2.FWD  5’ - AAA GGATCC A AT TAA TA ATG GAG GAC GGT AAA CAG G
Ste50.REV  5- AAA CCTAGG TTA GAG TCT TCC ACC GGG G
Ste11.K2.FWD 5'-AAAAAA  GGATCC ATTAAATA ATG GAA CAG ACA CAA ACA GCA GAG
Ste11.Stop.REV 5'- AAAA  CCTAGG TCA AATTATGTGTGCATCCAGCCATGGA
Ste7.K2.FWD 5'-AAAAAA  GGATCC ATTAAATA ATG TTT CAA CGA AAG ACT TTA CAG AGA AGG
Ste7.AvrII.REV 5’-  AAAAA CCTAGG TCA ATG GGT TGA TCT TTC CGA T
Fus3.K2.FWD 5'-AAAAAA  GGATCC ATTAAATA ATG CCA AAG AGA ATT GTA TAC AAT ATA TCC AG
Fus3.A. STOP.REV 5'-AAAAAA  CCTAGG CTA ACTA AAT ATT TCG TTC CAA ATG AGT TTC TTG AGG
MSG5.K2.FWD 5'- AAA GGATCC A AT TAA TA GTGCACATGCAATTTCAC
Msg5.REV 5'-AAAA  CCTAGG TTAAGGAAGAAACATCATCTG
pTEF1mut7 (55 )
pDS71 (56 )
pTEF7
pADH1
pFUS1
pCS13
pCYC1
pVS1 (57 )
 pVS10 (57 )
pCS14
 pNTI113 (20 )Ste4
pVS15 (57 )Fus3
Msg5 Genomic Msg5
Ste50
Ste11
Ste7
Genomic Ste50
  
Table S6. Galactose titration plasmids 
 
 
Table S7. Mutagenesis Primers 
 
 
 
 
 
 
pCS #  Cassette 3'UTR Marker
pCS1625 pGAL1-Ste4-ADH1t ON TRP
pCS1483 pGAL1-Ste11-ADH1t ON TRP
pCS1484 pGAL1-Ste7-ADH1t ON TRP
pCS1485 pGAL1-Fus3-ADH1t ON TRP
pCS1486 pGAL1-Msg5-ADH1t ON TRP
Primer Name Sequence Purpose
Ste4. XhoImut.FWD GTCACTGGTGTGCGATCGAGTCCAGATGG
Ste4. XhoImut.REV CCATCTGGACTCGATCGCACACCAGTGAC
Fus3-XHO.FWD GGAGAAGATGTTCCCTAGAGTCAACCCGAAAGG
Fus3-XHO.REV CCTTTCGGGTTGACTCTAGGGAACATCTTCTCC
Ste7-AvrII.FWD GTAACTGGAGAGTTTCCACTAGGTGGGCATAACGA
Ste7-AvrII.REV TCGTTATGCCCACCTAGTGGAAACTCTCCAGTTAC
pCS1441.XhoImut.FWD ATGCTGGCGGCCGCATCGAGAGATCTAAG
pCS1441.XhoImut.REV CTTAGATCTCTCGATGCGGCCGCCAGCAT
Remove XhoI from 
disintegrators
Remove XhoI in 
Ste4
Remove XhoI in 
Fus3
Remove AvrII in 
Ste7
  
Table S8. RNA transducers 
 
Note: Data for S3tc characterized in this study all other data acquired previously (24, 35).  
 
 
Switches Alias Sequence
Basal 
Expression                      
(0 mM)
 Induced 
Expression                                 
(th=5 mM;
tc= 1 mM)
ON sTRSV Ctrl
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTACGTGAGGTCCGTGA
GGACAGAACAGCAAAAAGAAAAATAAAAACTCGAG
100.0% 100.0%
OFF sTRSV
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTGA
GGACGAAACAGCAAAAAGAAAAATAAAAACTCGAG
1.2% 1.2%
S1th L2b8-a1         
AAACAAACAAAGCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGTTG
TCCATACCAGCATCGTCTTGATGCCCTTGGCAGGGACGGGACGGAGGACG
AAACAGCAAAAAGAAAAATAAAAACTCGAG
3.0% 8.0%
S2th L2b8-a1-t41 
AAACAAACAAAGCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGTTG
CGTATACCAGCATCGTCTTGATGCCCTTGGCAGACGGTAGACGGAGGACGA
AACAGCAAAAAGAAAAATAAAAACTCGAG
3.6% 12.7%
S3th L2b8-t47   
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTTGA
GTATACCAGCATCGTCTTGATGCCCTTGGCAGACTGTATACGGAGGACGAA
ACAGCAAAAAGAAAAATAAAAA
6.1% 33.6%
S4th L2b8             
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTTGT
CCATACCAGCATCGTCTTGATGCCCTTGGCAGGGACGGGACGGAGGACGA
AACAGCAAAAAGAAAAATAAAAACTCGAG
10.8% 36.7%
S5th L2b1
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTGTC
CATACCAGCATCGTCTTGATGCCCTTGGCAGGGACGGGACGAGGACGAAA
CAGCAAAAAGAAAAATAAAAA
39.8% 75.3%
S1tc L2b12tc-11
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTTGT
TGAAAACATACCAGATTTCGATCTGGAGAGGTGAAGAATTCGACCACCTCAT
TTCAACGGAGGACGAAACAGCAAAAAGAAAAATAAAAACTCGAG
3.7% 4.8%
S2tc L2b8tc-a1 
AAACAAACAAAGCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGTTG
TCCAAAACATACCAGATTTCGATCTGGAGAGGTGAAGAATTCGACCACCTG
GACGGGACGGAGGACGAAACAGCAAAAAGAAAAATAAAAACTCGAGCC
3.0% 10.8%
S3tc
L2b12tc-NheI-
L2bOFF1 
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTTGT
CCAAAACATACCAGATTTCGATCTGGAGAGGTGAAGAATTCGACCACCTGG
ACGGGACGGAGGACGAAACAGCAAAAAGAAAAATAAAAAGCTAGGAAAC
AAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTGTTGCTG
ATACCAGCATCGTCTTGATGCCCTTGGCAGCAGTGGACGAGGACGAAACA
GCAAAAAGAAAAATAAAAA    
4.2% 21.2%
S4tc L2b8tc 
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGTTGT
CCAAAACATACCAGATTTCGATCTGGAGAGGTGAAGAATTCGACCACCTGG
ACGGGACGGAGGACGAAACAGCAAAAAGAAAAATAAAAACTCGAG
8.4% 43.9%
Table S9. Primers for amplifying RNA transducers 
 
 
Table S10. Msg5 plasmids (URA) 
 
 
 
PCR Product Primer Name Sequence
Switch-Fwd 5'-GACCTAGGAAACAAACAAAGCTGTCACC
Switch-REV 5'-GGCTCGAGTTTTTATTTTTCTTTTTGCTGTTTCG
Switch.NheI.XhoI.REV 5’-TT CTCGAG TTTTTT GCTAGC TTTTTATTTTTCTTTTTGCTGTTTC
Switch3’sTRSVCtrl.XhoI.REV 5'-AAAACTCGAG TTTTTATTTTTCTTTTTGCTGTTCTG
Various Switches
pCS # Promoter 3'UTR
pCS2452 pADH1 Empty
pCS2453 pCYC1 Empty
pCS2454 pTEF7 Empty
pCS2455 pFUS1 Empty
pCS2456 pADH1 ON
pCS2457 pCYC1 ON
pCS2458 pTEF1 ON
pCS # 3'UTR
pCS2459 ON
pCS2460 S5th
pCS2461 S4th
pCS2462 S3th
pCS2463 S2th
pCS2464 S1th
pCS2465 OFF
pCS # 3'UTR
pCS2466 ON
pCS2467 S5th
pCS2468 S4th
pCS2469 S3th
pCS2470 S2th
pCS2471 S1th
pCS2472 OFF
pCS321+pTEF7-Msg5-SXth-ADH1t
pCS321+pX-Msg5-ADH11t
pCS321+pFUS1-Msg5-SXth-ADH1t
Table S11. Ste4 plasmids (URA) 
 
pCS # Promoter 3'UTR
pCS2473 pADH1 Empty
pCS2474 pCYC1 Empty
pCS2475 pFUS1 Empty
pCS2476 pADH1 ON
pCS2477 pCYC1 ON
pCS2478 pTEF1 ON
pCS # 3'UTR
pCS2479 ON
pCS2480 S4tc
pCS2481 S3tc
pCS2515 S2tc
pCS2483 S1tc
pCS2484 OFF
pCS # 3'UTR
pCS2485 ON
pCS2486 S5th
pCS2487 S4th
pCS2488 S2th
pCS2489 S1th
pCS2490 OFF
pCS # 3'UTR
pCS2491 S4tc
pCS2492 S2tc
pCS2493 S1tc
pCS # 3'UTR
pCS2494 ON
pCS2495 S4tc
pCS2496 S3tc
pCS2497 S2tc
pCS2498 S1tc
pCS2499 OFF
pCS # 3'UTR
pCS2500 S5th
pCS2501 S4th
pCS2502 S2th
pCS2503 S1th
pCS # 3'UTR
pCS2504 ON
pCS2505 S5th
pCS2506 S4th
pCS2507 S2th
pCS2508 S1th
pCS2509 OFF
pCS321+pX-Ste4-ADH1t
pCS2094+pFUS1-Ste4-SXtc-ADH1t
pCS321+pFUS1-Ste4-SXth-ADH1t
pCS321+pTEF7-Ste4-SXtc-ADH1t
pCS321+pADH1-Ste4-SXth-ADH1t
pCS321+pFUS1-Ste4-SXtc-ADH1t
pCS321+pTEF7-Ste4-SXth-ADH1t
Table S12. pCS2094 series dual expression cassette plasmids (URA) 
 
 
 
 
 
 
 
pCS # Downstream Cassette Upstream Cassette Marker
pCS2094 pTEF1-yEGFP-ON-ADH1t pTEF1-mcherry-CYC1t URA
pCS2515 pFUS1-Ste4-S2tc-ADH1t pTEF1-mcherry-CYC1t URA
pCS2516 pFUS1-Ste4-S2tc-ADH1t pTEF7-Msg5-OFF-ADH1t URA
pCS2517 pFUS1-Ste4-S2tc-ADH1t pTEF7-Msg5-S2th-ADH1t URA
pCS2518 pFUS1-Ste4-S2tc-ADH1t pTEF7-Msg5-S3th-ADH1t URA
pCS2519 pFUS1-Ste4-S2tc-ADH1t pTEF7-Msg5-S4th-ADH1t URA
pCS2520 pFUS1-Ste4-S2tc-ADH1t pTEF7-Msg5-ON-ADH1t URA
pCS2521 pFUS1-Ste4-OFF-ADH1t pTEF1-mcherry-CYC1t URA
pCS2522 pFUS1-Ste4-OFF-ADH1t pTEF7-Msg5-S2th-ADH1t URA
pCS2523 pFUS1-Ste4-OFF-ADH1t pTEF7-Msg5-S3th-ADH1t URA
pCS2524 pFUS1-Ste4-OFF-ADH1t pTEF7-Msg5-S4th-ADH1t URA
pCS2525 pFUS1-Ste4-OFF-ADH1t pTEF7-Msg5-ON-ADH1t URA
pCS2526 pFUS1-Ste4-S3tc-ADH1t pTEF1-mcherry-CYC1t URA
pCS2527 pFUS1-Ste4-S3tc-ADH1t pTEF7-Msg5-OFF-ADH1t URA
pCS2528 pFUS1-Ste4-S3tc-ADH1t pTEF7-Msg5-S2th-ADH1t URA
pCS2529 pFUS1-Ste4-S3tc-ADH1t pTEF7-Msg5-S3th-ADH1t URA
pCS2530 pFUS1-Ste4-S3tc-ADH1t pTEF7-Msg5-S4th-ADH1t URA
pCS2531 pFUS1-Ste4-S3tc-ADH1t pTEF7-Msg5-ON-ADH1t URA
pCS2532 pFUS1-Ste4-S4tc-ADH1t pTEF1-mcherry-CYC1t URA
pCS2533 pFUS1-Ste4-S4tc-ADH1t pTEF7-Msg5-OFF-ADH1t URA
pCS2534 pFUS1-Ste4-S4tc-ADH1t pTEF7-Msg5-S2th-ADH1t URA
pCS2535 pFUS1-Ste4-S4tc-ADH1t pTEF7-Msg5-S3th-ADH1t URA
pCS2536 pFUS1-Ste4-S4tc-ADH1t pTEF7-Msg5-S4th-ADH1t URA
pCS2537 pFUS1-Ste4-S4tc-ADH1t pTEF7-Msg5-ON-ADH1t URA
pCS2538 pFUS1-Ste4-ON-ADH1t pTEF1-mcherry-CYC1t URA
pCS2539 pFUS1-Ste4-ON-ADH1t pTEF7-Msg5-OFF-ADH1t URA
Table S13. pCS1128 series dual expression cassette plasmids (TRP) 
 
 
Table S14. Ste4 plasmids (TRP) 
 
pCS # Downstream Cassette Upstream Cassette Marker
pCS1128 None pGAL1-yEGFP-ON-ADH1t TRP
pCS2540 pFUS1-Ste4-OFF-ADH1t pTEF1-mcherry-CYC1t TRP
pCS2541 pFUS1-Msg5-OFF-ADH1t pTEF1-mcherry-CYC1t TRP
pCS2542 pFUS1-Msg5-OFF-ADH1t pTEF7-Ste4-S2tc-ADH1t TRP
pCS2543 pFUS1-Msg5-OFF-ADH1t pTEF7-Ste4-S3tc-ADH1t TRP
pCS2544 pFUS1-Msg5-OFF-ADH1t pTEF7-Ste4-S4tc-ADH1t TRP
pCS2545 pFUS1-Msg5-OFF-ADH1t pTEF7-Ste4-ON-ADH1t TRP
pCS2546 pFUS1-Msg5-S2th-ADH1t pTEF1-mcherry-CYC1t TRP
pCS2547 pFUS1-Msg5-S2th-ADH1t pTEF7-Ste4-OFF-ADH1t TRP
pCS2548 pFUS1-Msg5-S2th-ADH1t pTEF7-Ste4-S2tc-ADH1t TRP
pCS2549 pFUS1-Msg5-S2th-ADH1t pTEF7-Ste4-S3tc-ADH1t TRP
pCS2550 pFUS1-Msg5-S2th-ADH1t pTEF7-Ste4-S4tc-ADH1t TRP
pCS2551 pFUS1-Msg5-S2th-ADH1t pTEF7-Ste4-ON-ADH1t TRP
pCS2552 pFUS1-Msg5-S3th-ADH1t pTEF1-mcherry-CYC1t TRP
pCS2553 pFUS1-Msg5-S3th-ADH1t pTEF7-Ste4-OFF-ADH1t TRP
pCS2554 pFUS1-Msg5-S3th-ADH1t pTEF7-Ste4-S2tc-ADH1t TRP
pCS2555 pFUS1-Msg5-S3th-ADH1t pTEF7-Ste4-S3tc-ADH1t TRP
pCS2556 pFUS1-Msg5-S3th-ADH1t pTEF7-Ste4-S4tc-ADH1t TRP
pCS2557 pFUS1-Msg5-S3th-ADH1t pTEF7-Ste4-ON-ADH1t TRP
pCS2558 pFUS1-Msg5-S4th-ADH1t pTEF1-mcherry-CYC1t TRP
pCS2559 pFUS1-Msg5-S4th-ADH1t pTEF7-Ste4-OFF-ADH1t TRP
pCS2560 pFUS1-Msg5-S4th-ADH1t pTEF7-Ste4-S2tc-ADH1t TRP
pCS2561 pFUS1-Msg5-S4th-ADH1t pTEF7-Ste4-S3tc-ADH1t TRP
pCS2562 pFUS1-Msg5-S4th-ADH1t pTEF7-Ste4-S4tc-ADH1t TRP
pCS2563 pFUS1-Msg5-S4th-ADH1t pTEF7-Ste4-ON-ADH1t TRP
pCS2564 pFUS1-Msg5-ON-ADH1t pTEF1-mcherry-CYC1t TRP
pCS2565 pFUS1-Msg5-ON-ADH1t pTEF7-Ste4-OFF-ADH1t TRP
pCS2566 pFUS1-Msg5-ON-ADH1t pTEF7-Ste4-S2tc-ADH1t TRP
pCS2567 pFUS1-Msg5-ON-ADH1t pTEF7-Ste4-S3tc-ADH1t TRP
pCS # 3'UTR
pCS2510 S4tc
pCS2511 S3tc
pCS2512 S2tc
pCS2513 S1tc
pCS2514 OFF
pCS1128+pTEF7-Ste4-SXtc-ADH1t
Table S15. Integration plasmids 
 
 
Table S16. Yeast strains 
 
 
Table S17. Integrating Primers 
 
 
 
 
pCS #  Cassette Integration Loci Marker
pCS1391 LoxP Integrating plasmid (58 ) Primer-specific G418
pCS2292 pCS1391+pFUS1-yEGFP-ADH1t Primer-specific G418
CSY#
CSY364
CSY408
CSY505 CSY364 LYS2::pFUS1-GFP-ADH1t
CSY532
CSY840
Description
EY1119 from (59 ); W303a ∆sst1 ∆kss1::HIS3 
CSY364  Δgal2::KanR
CSY364  Δgal2::pFUS1-GFP-ADH1t-loxP-KanR-loxP
CSY364  Δtrp1::pFUS1-yEGFP3-ADH1t-loxP-KanR-loxP
Loci Sequence Direction
ATGCACCTTATTCAATTATCATCAAGAATAGTAATAGTTAAGTAAACACAA
GATTAACATAGATTGTACTGAGAGTGCAC FWD
ATGATAATTAAAATGAAGAAAAAACGTCAGTCATGAAAAATTAAGAGAG
ATGATGGAGCGCGACTCACTATAGGGAGACC REV
GTATACGTGATTAAGCACACAAAGGCAGCTTGGAGTATGTCTGTTATTAA
TTTCACAGGAAGATTGTACTGAGAGTGCAC FWD
TTGCTTTTCAAAAGGCCTGCAGGCAAGTGCACAAACAATACTTAAATAAA
TACTACTCAGCGACTCACTATAGGGAGACC REV
GAL2
TRP
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